Supplier
Presbyterian Healthcare Services
Presbyterian Healthcare Services was paid $8.66M by Medicaid between Jan 2018 and Mar 2024, across 10 billing codes. Its largest line is J0178, Injection, aflibercept, 1 mg — 25% of everything it billed.
33Billing provider infoPRESBYTERIAN HEALTHCARE SERVICES
ALBUQUERQUE, NM 87114
ALBUQUERQUE, NM 87114
33aNPI1932400397assigned 11/16/2010
33bProvider typePharmacy
28Total paid$8.66M
24GClaims9,402
24DCodes billed10
24AFirst – last monthJan 2018 – Mar 2024
Compared with peers
Next to other Pharmacy providers in New Mexico
Rank by total paid#1 of 9
Median peer was paid$2K
This provider vs. median3,991×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 714 | $751K | |
| 2019 | 1,031 | $1.05M | |
| 2020 | 1,399 | $1.77M | |
| 2021 | 1,996 | $2.26M | |
| 2022 | 1,764 | $1.69M | |
| 2023 | 1,825 | $609K | |
| 2024incomplete | 673 | $530K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 25% | 902 | 863 | $2.12M |
| J2357 | Injection, omalizumab, 5 mg | 23% | 1,231 | 813 | $2.01M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 15% | 2,135 | 1,408 | $1.32M |
| 90378 | 13% | 2,822 | 689 | $1.14M | |
| J7326 | Hyaluronan or derivative, gel-one, for intra-articular injection, per dose | 9.4% | 613 | 602 | $813K |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | 5.7% | 1,143 | 734 | $495K |
| J2778 | Injection, ranibizumab, 0.1 mg | 4.7% | 221 | 215 | $409K |
| J0897 | Injection, denosumab, 1 mg | 2.0% | 203 | 189 | $170K |
| J2315 | Injection, naltrexone, depot form, 1 mg | 1.3% | 96 | 96 | $109K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 36 | 26 | $74K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOWNING, ERICA (VP, PHARMACY AND INFUSION SERVICES)